Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside
SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma.
As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies. These technologies are already being investigated in Elpis' global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types. Plans are also underway for Elpis to establish a laboratory space at NCCS and co-share its equipment to enable more integrated and efficient collaboration.
"This partnership reflects our commitment to rapidly advancing innovative immunotherapies from discovery to clinical development through to regulatory review and, hopefully saving patients' lives," said Yan Chen, MD, PhD, Founder and CEO of Elpis Biopharmaceuticals. "By combining Elpis's proprietary technology with NCCS's clinical expertise, we look forward to accelerating the delivery of these potential groundbreaking new cancer therapies to patients in Singapore and beyond."
NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates.
"The potential of using cell therapies for solid tumors is still being explored, and this collaboration will enable us to evaluate promising new technologies in a clinical context to address current unmet needs and improve patient outcomes," said Professor Lim Soon Thye, CEO of NCCS.
"This is a key collaboration with NCCS' precision immunotherapy program. With our respective strengths and the shared goal of transforming clinical care through translational science, we look forward to offering clinical trials and developing novel cell therapies to better meet the needs of patients in Singapore and the region," added Professor Daniel Tan, Head, Division of Clinical Trials and Epidemiological Sciences and Senior Consultant, NCCS.
The collaboration will support the development of bispecific armored CAR-T cell therapies for solid tumors, while Elpis's global leading mRNA display technology will support NCCS in the rapid discovery of human antibodies to novel targets and enable novel modalities to cell therapy and beyond.
"The MOU represents an expansion of Elpis's living drug strategy and a key step toward enabling broader clinical translation of our cutting-edge cell therapy technologies," said Chee-Yong Lim, Co-Founder, Co-CEO & Chief Strategy Officer, Elpis Biopharmaceuticals. "Together, we are working to make living drugs a reality for patients with cancers that currently lack effective treatment options."
About Elpis Biopharmaceuticals
Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis's lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Singapore and Boston, MA. For more information, visit www.elpisbiopharmaceuticals.com.
Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent (investors)
+1-205-566-3026
jnugent@tiberend.com
Eric Reiss (media)
ereiss@tiberend.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore
Arrival further strengthens the firm's premier Antitrust & Competition Practice in Europe and enhances its unrivalled global platform.
PARIS, Sept. 19, 2026 /PRNewswire/ -- Latham & Watkins is pleased to announce that Victor Levy has joined the firm's Paris office as partner in its Antitrust & Competition Practice. Levy advises on competition law matters, with particular experience in merger control filings before the European Commission, the French Competition Authority, and other competition authorities globally, as well as complex antitrust investigations and follow-on damages claims before competition authorities and Courts.
Levy has extensive experience across sectors including aerospace and defense, consumer goods, and industrials.
"We are thrilled to welcome Victor to the firm," said Thomas Margenet-Baudry, Office Managing Partner of Latham & Watkins in Paris. "Our Paris office is a powerhouse in the French market, with exceptional strength across our transactional and regulatory practices. Antitrust and competition is central to that success, an essential component of our market-leading transactional and litigation platforms and a formidable go-to practice. Victor brings deep experience in complex domestic and cross-border antitrust matters for French and international clients that complements our existing strengths and further enhances the sophisticated, integrated advice we provide to clients in France, across Europe, and globally. His arrival reflects our ambition to continue investing in the very best talents and to remain at the forefront of the market for years to come."
Latham's Antitrust & Competition Practice is widely recognized as one of the world's premier antitrust platforms, delivering sophisticated, coordinated advice across the United States, Europe, and Asia. The firm advises and represents clients on many of their most significant and complex global transactions, cartel investigations, and disputes, combining deep antitrust experience with market-leading litigation and trial capabilities. The Paris competition practice, like that of the Brussels office, is ranked Band 1 / Tier 1 in the legal directories. The addition of Levy further strengthens the firm's European and Paris bench and enhances its ability to guide clients through an increasingly complex and interconnected global competition and regulatory landscape.
"The addition of Victor underscores the continued strength and momentum of our global practice," said Lawrence Buterman, Global Chair of Latham's Antitrust & Competition Practice. "Our platform brings together leading antitrust lawyers across the United States, Europe, and Asia who are increasingly called upon by our clients to lead and coordinate representations on complex transactions and litigation matters spanning multiple jurisdictions. Victor brings outstanding credentials and deep experience that will further strengthen our ability to deliver integrated and global solutions at the highest level."
"We have known Victor for many years and have long held him in the highest regard," said Jacques-Philippe Gunther, Antitrust & Competition partner in Paris. "He is definitely one of the best of his generation, and his unique combination of economic and legal expertise makes him a real additional strength to our talented team."
Paris Antitrust & Competition partner, Adrien Giraud also commented: "Victor brings extensive experience across merger control, foreign investment screening, antitrust investigations, litigation, and State aid. At a time when antitrust and regulatory considerations are playing a critical role in shaping strategic business decisions, his arrival further enhances the breadth and depth of our offering in Paris."
"I am delighted to join Latham & Watkins in Paris, especially at this critical time when competition authorities are becoming increasingly active and coordinated across jurisdictions. The firm's global platform and market-leading capabilities provide an exceptional opportunity to help clients navigate their most complex matters," said Levy. "I look forward to working closely with the teams across practices and geographies to further develop Latham's antitrust and competition offering."
Levy joins Latham & Watkins from Hogan Lovells Cadwalader. He holds a Master's degree in Mathematics from the École Normale Supérieure de Lyon, a Master's degree in European Business Law from Paris Panthéon-Assas University, and an LL.M. from New York University School of Law. He is admitted to practice in Paris and New York.
About Latham & Watkins (lw.com)
Latham & Watkins is a leading global law firm that brings together exceptional legal talent in financial centers around the world to advise on complex transactions, litigation, and regulatory matters. The firm's deep market and product knowledge, industry experience, vast scale, and commitment to innovation and excellence help clients navigate their most critical challenges and achieve their goals.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Latham Expands Market-Leading Antitrust & Competition Practice with Paris Partner Victor Levy
